Merck: new indication approved for Keytruda in Europe
Brussels' approval covers, more specifically, the combination of Keytruda with chemotherapy in the neoadjuvant (pre-operative) treatment of the disease, then as monotherapy as adjuvant therapy.
Merck points out that this is the first time that an anti-PD-1/L1 therapy has been approved for the treatment of operable non-small cell lung cancer in Europe.
This is the sixth indication for Keytruda in the treatment of bronchial cancer on the Old Continent.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction